T h e W o r k : P rofessional A dvertising Raising the survival standard as observed in pivotal Phase III trials" r ' NSCLC MCRC MCRC 1 0 . 3 - . 1 2 . 3 months months 1 5 . 6 .. 2 0 . 3 months months 1 0 . 8 . 1 3 . 0 months months 1. AGENCY: Topin & Associati CREATIVE TEAM: John Dii Maija Kroeger CLIENT: Sirius Labs 2. AGENCY: Harrison & Star CREATIVE TEAM: Chris Watson, Kevin McShane, Mil Norkin, Kristen Goldrick, Jim Newton, Rob DeNivo CLIENT: Genentech 3. AGENCY: KPR CREATIVE TEAM: Frederic Rescott, Letty Albarreu CLIENT: Merck Avaslin is recognized by the NCCN' as a standard of care for appropriate patient types in combination with first-line IV chemotherapy'" AVASTIN ( bevacizumab X. Reach beyond convention In first-line metastatic NSCLC and first- or second-line MCRC umof aditional INVANZ is indicated for the treatment of aduit patterns with the fof:»-rg moderate to severe infections caused by susceptible strains of the desgnated uucroorgams.'Tis: Complicated intra-abdominal infections due to Cscheiichia cofi, Clostridium dostiM dm e. Cuiactemm Jenfum, fleptostrepfococcus species. Bactemides tragiSs. Bactemides disfasoras. Bxtmdes matus, Sactenxdes thetaiotaomicmn, or 8actero«fes uniforms. Complicated skin/skin structure infections due to Staphylococcus aureus (metfitaifn-suscepbble starts only). Streptococcus pyogenes, fscfrerfctiia coS. or Peptoslreptococcus species. Appropriate specimens for bacteriological examination should be obtained in order to iso^re and identify the causative organisms and to determine their suscepbbaty to INVANZTherapy with INVANZ may be initialed empuicaliy before results of these tests are known: once results become available, antimicrobial therapy should be adjusted acconfcigr/. INVANZ is contraindicated m patents with known hypersensitivity to airy component of tbs product or to other drugs in the same class or in patents who hare demonstrated anaphylactic reactions to beta-lactams. Due to the use of Idocame HO as a dtuent. INVANZ administered intramuscularty is contraindicated in patients with a known tr,peisens:bwy to local anesthetics of the amide type. (Refer to the presatbing mformabon for Sdocame HO.) During clinical imesSgations in adult patents treated with INVANZ (1 g once a day), seizures, irrespective of drug relationship, occurred n 0.556 of patients dunng study therapy plus 14-day foitaw-ap period. These experiences have occurred most commonly in patents with CNS disordera (eg. bram lesions or history of seizures) and/or compromised renal function. Close adherence to the recommended dosage regimen is urged, especially in patients wsh known factois that predispose to convuiSNe activity. N The most common drug-related adverse experiences in patients treated with H T , INVANZ including those who were switched to therapy with an oral antimicrobial, were dianhea (5.5%). infused vein compicaton (3.7%), ■ f c V mse> (3.1%), headache (2.2%). vaginitis m females (2.1%). phlebibs/thrombophlebtis (1.3%). and vwr,rung (11%). ONCE-A-DAY The Power of One One Gram; One Dose, Once a Day A simplified dosing regimen for the treatment of moderate to severe complicated intra-abdominal and complicated skin/skin structure infections ‘Patients with advanced renal insufficiency (creatinine clearance <30 ml/min/1.73 m1) and end-stage renal insufficiency (creatinine clearance <10 mL/min/1.73 nf) should receive 500 mg daily. Vi Cease read the 8nef$cmriaiy of Prescntw'glnkKmatioi! on the aefceent page. w M MERCK 202040l ltlKOOO! t 157
RkJQdWJsaXNoZXIy NDMwNDAx